GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...

Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its ...

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...